Skip to NavigationSkip to content

Eli Lilly

US Judge blocks Trump administration law requiring pharma to include prices in TV ads

A judge has blocked the Trump administration from enacting a law that would require pharmaceutical companies to include the prices of their drugs in TV ads.

On 8 July 2019, District Judge Amit Mehta in Washington, DC ruled in favour of pharma giants Amgen, Eli Lilly and MSD in preventing the Department of Health and Human Services (HHS) new law from taking effect.

Drugmakers sue Trump over prices in TV ads

Amgen, Eli Lilly and MSD have sued the Trump administration to try and block measures to force pharma companies to include prices in TV ads.

Three of America’s biggest drugmakers filed a lawsuit against the Trump administration over the Department of Health and Human Services (HHS) ruling to force pharmaceutical companies to list the prices of their drugs in adverts on TV.

Eli Lilly's heart drug underwhelms with REWIND trial

Eli Lilly’s Trulicity (dulaglutide) reduced major cardiovascular events (MACE) by 12% versus placebo in adults with type 2 diabetes, according to the results of the REWIND trial.

The study of 9901 adults with type 2 diabetes looked at the glucagon-like peptide 1 receptor agonist Trulicity in combination with standard of care treatment in comparison to standard of care treatment combined with placebo.

Eli Lilly's Emgality approved in the US for episodic cluster headache

Eli Lilly’s Emgality (galcanezumab-gnlm) self-administered injection solution has secured approval in the US for the treatment of episodic cluster headache, it has emerged.

The therapy showed its efficacy in the approved indication in a trial of 106 patients. Participants were measured for their average number of cluster headaches per week for three weeks to establish a baseline; it was found that Lilly’s drug reduced the average number of attacks by 8.7 on average from baseline, compared to a reduction of 5.2 with placebo.

Japan's health ministry warns of serious side effects of Lilly's Verzenio

Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs.

The health ministry said Verzenio is suspected of adversely affecting patients’ lungs after 14 patients developed a serious lung disease and three died.

The drug has been blamed for at least four of the 14 cases of lung disease, one of which resulted in death.

Lilly's Cyramza approved in US for hepatocellular carcinoma sub-population

Eli Lilly's vascular endothelial growth factor (VEGF) receptor 2 antagonist Cyramza (ramucirumab) has received approval in the US as a single agent for the treatment of hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥400 ng/mL and have been previously treated with Bayer’s Nexavar (sorafenib), the FDA has confirmed.

In a study of 292 patients in this indication, it was demonstrated that Cyramza, when combined with best supportive care (BSC) and administered every two weeks, improved median overall survival by 8.5 months, compared to 7.3 months

Top Ten most popular articles on this week!

This week was a particularly bad one for the NHS after it was revealed thousands of EU nurses were leaving while the number of GPs had gone into decline for the first time in 50 years. Meanwhile our feature looked at the NHS Long Term Plan and asked to what extent mHealth will go towards solving the problems of the overstretched National Health Service.

Eli Lilly's Emgality shows positive Phase 3 results in treatment of migraine

Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the treatment of episodic migraine.

The drug was found to reduce the number of migraine headache days patients experienced each month, in comparison to placebo.

Patients – who were categorised as either low-frequency (four to seven migraine days a month) or high-frequency (eight to 14 monthly migraine days a month) – were given either 120mg or 240mg doses of Lilly’s Emgality.

Top Ten most popular articles on this week!

This week was marked by the failure of two Phase 3 trials after both Eli Lilly and Gilead suffered from poor results in late stage studies. Lilly’s failure was so such that they decided to withdraw Latruvo from the market.

Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure

Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from the market as a treatment for advanced soft tissue sarcoma (STS) due to the drug’s failure to adequately address the condition in Phase 3 trials.

Lartruvo failed to meet its primary endpoint of improvement in overall survival in the ANNOUNCE trial earlier this year.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches